Results of the January 2019 Innovation to Impact Grants competition

We are pleased to announce the results of the most recent Innovation to Impact Grants competition to support the further development of successful findings based on the goals originally explored through a CCS Innovation Grant or eligible CBCF grant. Below is a listing of newly awarded Innovation to Impact Grants.

Out of a total of 51 grant applications reviewed, 18 Canadian Cancer Society Innovation to Impact Grants have been approved – a 35% success rate. Funds committed to this competition have been made possible by the significant efforts of CCS donors and volunteers across the country. These projects total more than $7.7 million in funding over the full term of these grants.

Abstracts of i2I Grants

 Please note: 

  • Amounts listed below represent the total dollars awarded by grant year and may include funds for salaries, supplies, and/or equipment.
  • The start date for these grants is August 1, 2019.
  • Only the Principal Investigator is named in this listing. Co-Principal Investigators, Co-Applicants and/or Additional Authors may also be associated with these grants.


Note Carefully:

Although every effort has been made to ensure the accuracy of the listing below, this list does not constitute an "official" notification.

Successful applicants will be informed, in writing, with an official Notification of Award giving the details pertaining to their grant.

Applicant
Institution
Title
Award
Chan, Warren
University of Toronto
Artificially increased nanoparticle delivery efficiency for solid tumours

2019/2020 :  $150,000
2020/2021 :  $150,000
2021/2022 :  $150,000
Egan, Sean
The Hospital for Sick Children
Modelling hormone resistant Invasive lobular breast cancer as a platform for development of novel treatment strategies

2019/2020 :  $149,825
2020/2021 :  $149,825
2021/2022 :  $149,825
Hakem, Razqallah
Princess Margaret Cancer Centre UHN
Identification of novel synthetic lethal therapeutic targets for BRCA1/2 defective and other homologous recombination deficient breast and ovarian cancers

2019/2020 :  $150,000
2020/2021 :  $150,000
2021/2022 :  $150,000
Jiang, Xiaoyan
BC Cancer, part of the Provincial Health Services Authority
A novel treatment approach to overcome TKI resistance in BCR ABL+ human leukemia

2019/2020 :  $150,000
2020/2021 :  $150,000
2021/2022 :  $150,000
Khokha, Rama
Princess Margaret Cancer Centre UHN
Targeting cell of origin in the high risk breast for molecular interception

2019/2020 :  $150,000
2020/2021 :  $150,000
2021/2022 :  $150,000
Klassen, Anne
McMaster University
Phase 2 field test study to validate new BREAST Q scales

2019/2020 :  $140,254
Liu, Fei Fei
Princess Margaret Cancer Centre UHN
Developing an anti fibrosis treatment to improve cancer survivorship

2019/2020 :  $150,000
2020/2021 :  $150,000
2021/2022 :  $150,000
Meloche, Sylvain
Université de Montréal
Identification and preclinical development of small molecule inhibitors of the cancer related ubiquitin conjugating enzyme UBCH10

2019/2020 :  $150,000
2020/2021 :  $150,000
2021/2022 :  $150,000
Mossman, Karen
McMaster University
Evaluation of the role of B cells in oncolytic virus therapy that sensitizes triple negative breast cancer to checkpoint blockade immunotherapy

2019/2020 :  $147,000
2020/2021 :  $148,000
2021/2022 :  $150,000
Pelletier, Laurence
Mount Sinai Hospital
A centrosome Wnt PCP signalling axis in cancer cell motility and metastasis

2019/2020 :  $149,666
2020/2021 :  $149,666
2021/2022 :  $149,666
Postovit, Lynne Marie
University of Alberta
Plasticity and the breast tumour microenvironment

2019/2020 :  $150,000
2020/2021 :  $150,000
2021/2022 :  $150,000
Rafei, Moutih
Université de Montréal
Defining the role of interleukin 21 in primary lymphatic organs: towards optimal stem cell transplantation

2019/2020 :  $150,000
2020/2021 :  $150,000
2021/2022 :  $150,000
Reilly, Raymond
University of Toronto
Radiation nanomedicine for local treatment of metastases from triple negative breast cancer

2019/2020 :  $149,563
2020/2021 :  $148,669
2021/2022 :  $143,610
Reznik, Alla
Lakehead University
Incorporating advanced capabilities in best in class PEM system for improved clinical outcomes

2019/2020 :  $149,800
2020/2021 :  $149,000
2021/2022 :  $150,000
Sabiston, Catherine
University of Toronto
Connecting breast cancer survivors for exercise: extending the impact of ActiveMatch

2019/2020 :  $114,681
2020/2021 :  $150,000
2021/2022 :  $148,149
Sabourin, Luc
Ottawa Hospital Research Institute
Transcriptional reprogramming by Akt Sox9 in HER2+ SLK deficient breast cancer

2019/2020 :  $150,000
2020/2021 :  $150,000
2021/2022 :  $150,000
Sawka, Annie
The Toronto Hospital (General Division) UHN
Active surveillance of low risk papillary thyroid cancer: program expansion in quebec

2019/2020 :  $150,000
2020/2021 :  $150,000
2021/2022 :  $150,000
Yamanaka, Yojiro
McGill University
Developing detection strategies and elucidating mechanisms controlling peritoneal metastasis of ovarian cancer

2019/2020 :  $150,000
2020/2021 :  $150,000
2021/2022 :  $150,000

Last modified on: December 2, 2019